Norgestrel Shortage: What Providers and Prescribers Need to Know in 2026

Norgestrel (Opill) is not currently listed on the FDA drug shortage database. As of 2026, it is available over the counter (OTC) at major retail pharmacy chains, grocery stores, and online distributors nationwide. However, providers should understand several nuanced access issues that affect patients — and know what to do when patients return to the clinic unable to obtain their preferred contraceptive.

This guide is written for OB/GYNs, family medicine physicians, nurse practitioners, and physician assistants managing contraception for patients in 2026.

Current Supply Status: No FDA-Documented Shortage

Opill (norgestrel 0.075 mg) is manufactured by Perrigo and distributed through a national supply chain. It is not on the FDA's CDER drug shortage list and has not been in shortage at any point since its OTC launch in March 2024. Perrigo has maintained consistent supply across its retail and online distribution network.

When patients report difficulty accessing norgestrel, the cause is generally not a supply chain disruption. Rather, it reflects the structural differences between OTC and prescription drug distribution, patient cost burden, and geographic disparities in retail pharmacy access.

Understanding the OTC Distribution Model and Patient Access Barriers

Prescription contraceptives are delivered through a pharmacy benefits system that provides reliable dispensing with insurance adjudication at the point of sale. OTC products like Opill operate differently — they are stocked by individual retail buyers at each chain, subject to shelf rotation decisions, and are not automatically sent to patients through mail-order pharmacy programs.

Key access barriers your patients may face include:

• Insurance coverage gaps. The ACA mandates no-cost coverage for FDA-approved contraceptives, but this applies to prescription drugs. There is currently no federal requirement for plans to cover OTC contraceptives without a prescription. Patients accustomed to zero-copay birth control may face an unexpected out-of-pocket expense of $20/month.
• Rural pharmacy deserts. Independent pharmacies in rural or underserved communities may not routinely stock Opill, and internet access limitations can make online ordering difficult for some populations.
• Inconsistent shelf stocking. Even major chain pharmacies may intermittently stock out at individual locations. OTC products do not have the fill-or-substitute mandates that apply to prescription drugs.
• Patient confusion about OTC status. Some patients are unaware that Opill is now OTC and still seek a prescription from their provider before attempting to purchase it.

Pharmacological Overview: Norgestrel 0.075 mg

Norgestrel is a synthetic progestogen (second-generation progestin) and agonist at the progesterone receptor. It is a racemic mixture, with the active component being levonorgestrel (the levo enantiomer). At the 0.075 mg OTC dose, the primary mechanism of action is thickening of cervical mucus to impair sperm motility and penetration. Ovulation suppression occurs in approximately 50% of cycles based on ultrasound-monitored pharmacodynamic studies.

It has weak androgenic activity and no estrogenic, antiestrogenic, or antimineralocorticoid activity. Peak serum levels are reached within 2 hours of administration, with near-baseline levels by 24 hours — which explains the strict 3-hour missed-pill window and the importance of consistent daily timing.

Contraindications and Clinical Eligibility

Norgestrel (OTC or prescription) is contraindicated in patients with:

• Current or history of breast cancer
• Current pregnancy
• Known allergy to norgestrel or product ingredients (including tartrazine/Yellow No. 5)

Unlike estrogen-containing contraceptives, progestin-only pills like norgestrel are generally appropriate (U.S. MEC Category 1 or 2) for patients with hypertension, migraine with aura, DVT/VTE history, cardiovascular disease, and smokers over 35.

Evidence-Based Alternatives When Norgestrel Is Not Accessible

When a patient prefers or requires a progestin-only method and Opill is not accessible to them, consider the following clinical alternatives:

• Norethindrone 0.35 mg: The prescription progestin-only pill most analogous to norgestrel. Covered under ACA at zero copay for most plans. Efficacy and mechanism are similar; same 3-hour missed-pill window. Generic available from multiple manufacturers.
• Drospirenone 4 mg (Slynd): Offers consistent ovulation suppression and a 24-hour missed-pill window. Anti-androgenic and antimineralocorticoid activity may benefit patients with PCOS, acne, or water retention. Contraindicated in renal impairment and adrenal insufficiency due to potassium retention. Generic now available.
• Etonogestrel implant (Nexplanon): For patients who prefer long-acting reversible contraception. >99% effective for 3 years. No adherence concerns. Covered at $0 by most plans.
• Levonorgestrel IUD (Mirena, Liletta, Kyleena): Progestin delivered locally; low systemic exposure. 5–8 year efficacy. >99% effective. Often preferred for patients who want long-term, low-maintenance contraception without daily adherence requirements.

Helping Patients Navigate Access and Cost

Providers can play an important role in bridging access gaps for patients who want norgestrel but can't afford OTC pricing. Consider the following steps:

1. Advise patients that HSA and FSA funds can be used to purchase Opill.
2. Direct patients to the Opill Cost Assistance Program (OpillCAP.com) for income-based assistance.
3. If a patient needs insurance coverage, write a prescription for norgestrel — some plans will cover it when prescribed, even though it's also OTC.
4. For patients who struggle with daily adherence, discuss long-acting options such as Nexplanon or a hormonal IUD.

medfinder also partners with healthcare providers to help patients locate medications quickly. Learn more at medfinder.com/providers.

See also: How to help your patients find Norgestrel in stock: A provider's guide.